<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968201</url>
  </required_header>
  <id_info>
    <org_study_id>0476-072</org_study_id>
    <secondary_id>2009_651</secondary_id>
    <nct_id>NCT00968201</nct_id>
  </id_info>
  <brief_title>Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Parallel-Group Chronic Asthma Study Comparing Montelukast With Placebo in 2- to 5-Year-Old Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in 2-5 year old children to evaluate the safety and tolerability of montelukast and
      placebo administered once daily at bed time.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1997</start_date>
  <completion_date type="Actual">March 2001</completion_date>
  <primary_completion_date type="Actual">March 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Drug-related CAEs Reported by Patients - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious CAEs Reported by Patients - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious Drug-related CAEs Reported by Patients - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients who reported serious drug-related CAEs during 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to CAEs - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients who were discontinued due to CAEs during 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Drug-related CAEs - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients who were discontinued due to drug-related CAEs during 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Serious CAEs - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients who were discontinued due to serious CAEs during 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Adverse Experiences (LAEs) - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to LAEs - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients who were discontinued due to LAEs during 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Drug-related LAEs - Base Study</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients who were discontinued due to drug-related LAEs during 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Drug-related CAEs Reported by Patients - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious CAEs Reported by Patients - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious Drug-related CAEs Reported by Patients - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who reported serious drug-related CAEs up to 2.8 years of
treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to CAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who were discontinued due to CAEs up to 2.8 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Drug-related CAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who were discontinued due to drug-related CAEs with up to 2.8 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Serious CAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who were discontinued due to serious CAEs with up to 2.8 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Serious Drug-related CAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who were discontinued due to serious drug-related CAEs with up to 2.8 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Adverse Experiences (LAEs) - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious LAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious Drug-related Laboratory Adverse Experiences (LAEs) - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who reported serious drug-related LAEs up to 2.8 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to LAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who were discontinued due to LAEs up to 2.8 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Drug-related LAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who were discontinued due to drug-related LAEs with up to 2.8 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Serious LAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who were discontinued due to serious LAEs with up to 2.8 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Discontinued Due to Serious Drug-related LAEs - Extension</measure>
    <time_frame>up to 2.8 years</time_frame>
    <description>Patients who were discontinued due to serious drug-related LAEs with up to 2.8 years of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">689</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>one chewable placebo tablet, once daily at bedtime for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has history of physician diagnosed asthma

          -  Patient is in otherwise good stable health

          -  Patient is able to chew a tablet

        Exclusion Criteria:

          -  Patient is hospitalized

          -  Patient and/or parent of guardian intends to move or vacation away from home during
             the course of the study

          -  Patient had any major surgical procedure within 4 weeks before the study

          -  Patient had active sinus disease within 3 weeks before the study

          -  Patient had required intubation for asthma in the past

          -  Patient required a visit to the emergency room due to an asthma exacerbation, or has
             been hospitalized for asthma with in 1 month prior to the study

          -  Patient had used inhaled, nebulized, intramuscular, or intravenous steroids with in 1
             month before study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001 Sep;108(3):E48.</citation>
    <PMID>11533366</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <results_first_submitted>September 15, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2010</results_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Base Study: 93 sites in the United States (US) and other countries in Africa, Australia, Europe, North America, and South America. Therapy period: Dec-1997 to Mar-1999.
Extension Study: 75 sites in the US and other countries in Africa, Australia, Europe, North America, and South America. Therapy period: Mar-1998 to Mar-2001.</recruitment_details>
      <pre_assignment_details>Base Study: Patients who required excluded medication and those who did not meet a minimum predefined level of asthma symptoms and β-agonist use during run-in (Period I) were excluded from randomization (Period II).
Extension Study (Period III): Patients who did not complete Visit 9 of Base Study were not eligible for the optional Extension.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some
patients receiving montelukast in Period II were switched to usual care in the Extension Study.
Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
        </group>
        <group group_id="P3">
          <title>Montelukast</title>
          <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.
Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at
their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study - (Period II)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="228">Includes patients who completed Period I (2-week placebo run-in) and were randomized to placebo.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="461">Includes patients who completed Period I (2-week placebo run-in) and were randomized to montelukast.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202">Patients completing Period II were eligible to enter the optional Period III</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="416">Patients completing Period II were eligible to enter the optional Period III</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study - (Period III)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="157">Eligible Patients who completed Period II and entered the optional Extension Study (Period III)</participants>
                <participants group_id="P3" count="364">Eligible Patients who completed Period II and entered the optional Extension Study (Period III)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="280"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Relocated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated for Admin Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="185"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Montelukast</title>
          <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="228"/>
            <count group_id="B2" value="461"/>
            <count group_id="B3" value="689"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.62" spread="1.10"/>
                    <measurement group_id="B2" value="3.58" spread="1.11"/>
                    <measurement group_id="B3" value="3.59" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Drug-related CAEs Reported by Patients - Base Study</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication were included in the analysis.
Drug relationship for 1 patient in the Placebo group should have been listed as definitely not drug related.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related CAEs Reported by Patients - Base Study</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
          <population>All patients who took study medication were included in the analysis.
Drug relationship for 1 patient in the Placebo group should have been listed as definitely not drug related.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Drug-Related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Drug-Related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious CAEs Reported by Patients - Base Study</title>
        <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication were included in the analysis.
A serious CAE (study drug overdose) prior to randomization in the Placebo group is not included in this number</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious CAEs Reported by Patients - Base Study</title>
          <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
          <population>All patients who took study medication were included in the analysis.
A serious CAE (study drug overdose) prior to randomization in the Placebo group is not included in this number</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious Drug-related CAEs Reported by Patients - Base Study</title>
        <description>Patients who reported serious drug-related CAEs during 12 weeks of treatment</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Drug-related CAEs Reported by Patients - Base Study</title>
          <description>Patients who reported serious drug-related CAEs during 12 weeks of treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to CAEs - Base Study</title>
        <description>Patients who were discontinued due to CAEs during 12 weeks of treatment</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to CAEs - Base Study</title>
          <description>Patients who were discontinued due to CAEs during 12 weeks of treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Drug-related CAEs - Base Study</title>
        <description>Patients who were discontinued due to drug-related CAEs during 12 weeks of treatment</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Drug-related CAEs - Base Study</title>
          <description>Patients who were discontinued due to drug-related CAEs during 12 weeks of treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Serious CAEs - Base Study</title>
        <description>Patients who were discontinued due to serious CAEs during 12 weeks of treatment</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Serious CAEs - Base Study</title>
          <description>Patients who were discontinued due to serious CAEs during 12 weeks of treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Adverse Experiences (LAEs) - Base Study</title>
        <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Adverse Experiences (LAEs) - Base Study</title>
          <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Base Study</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Base Study</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Drug-Related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Drug-Related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to LAEs - Base Study</title>
        <description>Patients who were discontinued due to LAEs during 12 weeks of treatment</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to LAEs - Base Study</title>
          <description>Patients who were discontinued due to LAEs during 12 weeks of treatment</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Drug-related LAEs - Base Study</title>
        <description>Patients who were discontinued due to drug-related LAEs during 12 weeks of treatment</description>
        <time_frame>12 weeks of treatment</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Drug-related LAEs - Base Study</title>
          <description>Patients who were discontinued due to drug-related LAEs during 12 weeks of treatment</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to Drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Extension</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Extension</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Drug-related CAEs Reported by Patients - Extension</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related CAEs Reported by Patients - Extension</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious CAEs Reported by Patients - Extension</title>
        <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious CAEs Reported by Patients - Extension</title>
          <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious Drug-related CAEs Reported by Patients - Extension</title>
        <description>Patients who reported serious drug-related CAEs up to 2.8 years of
treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Drug-related CAEs Reported by Patients - Extension</title>
          <description>Patients who reported serious drug-related CAEs up to 2.8 years of
treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to CAEs - Extension</title>
        <description>Patients who were discontinued due to CAEs up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to CAEs - Extension</title>
          <description>Patients who were discontinued due to CAEs up to 2.8 years of treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Drug-related CAEs - Extension</title>
        <description>Patients who were discontinued due to drug-related CAEs with up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Drug-related CAEs - Extension</title>
          <description>Patients who were discontinued due to drug-related CAEs with up to 2.8 years of treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Serious CAEs - Extension</title>
        <description>Patients who were discontinued due to serious CAEs with up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Serious CAEs - Extension</title>
          <description>Patients who were discontinued due to serious CAEs with up to 2.8 years of treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Serious Drug-related CAEs - Extension</title>
        <description>Patients who were discontinued due to serious drug-related CAEs with up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Serious Drug-related CAEs - Extension</title>
          <description>Patients who were discontinued due to serious drug-related CAEs with up to 2.8 years of treatment</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Serious Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Discontinued Due to Serious Drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Adverse Experiences (LAEs) - Extension</title>
        <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Adverse Experiences (LAEs) - Extension</title>
          <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Extension</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Extension</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious LAEs - Extension</title>
        <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication and had any laboratory tests performed were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious LAEs - Extension</title>
          <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
          <population>All patients who took study medication and had any laboratory tests performed were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious Drug-related Laboratory Adverse Experiences (LAEs) - Extension</title>
        <description>Patients who reported serious drug-related LAEs up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Drug-related Laboratory Adverse Experiences (LAEs) - Extension</title>
          <description>Patients who reported serious drug-related LAEs up to 2.8 years of treatment</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious Drug-Related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious Drug-Related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to LAEs - Extension</title>
        <description>Patients who were discontinued due to LAEs up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to LAEs - Extension</title>
          <description>Patients who were discontinued due to LAEs up to 2.8 years of treatment</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Drug-related LAEs - Extension</title>
        <description>Patients who were discontinued due to drug-related LAEs with up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Drug-related LAEs - Extension</title>
          <description>Patients who were discontinued due to drug-related LAEs with up to 2.8 years of treatment</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to Drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Serious LAEs - Extension</title>
        <description>Patients who were discontinued due to serious LAEs with up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Serious LAEs - Extension</title>
          <description>Patients who were discontinued due to serious LAEs with up to 2.8 years of treatment</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue Due to Serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Discontinued Due to Serious Drug-related LAEs - Extension</title>
        <description>Patients who were discontinued due to serious drug-related LAEs with up to 2.8 years of treatment</description>
        <time_frame>up to 2.8 years</time_frame>
        <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Discontinued Due to Serious Drug-related LAEs - Extension</title>
          <description>Patients who were discontinued due to serious drug-related LAEs with up to 2.8 years of treatment</description>
          <population>All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued Due to Serious Drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Discontinued Due to Serious Drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 12 week base study (Period II) and 36 month extension study (Period III) and up to and including 14 days after the last dose of study therapy.</time_frame>
      <desc>Although patient may have had 2 or more clinical adverse experiences, patient is counted only once in a category. The same patient may appear in different categories. Adverse events (AEs) in Period II have 0/0 for Usual Care group because there was no Usual Care group. AEs in Period III have 0/0 for Placebo group because there was no Placebo group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>“Usual care,” defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some
patients receiving montelukast in Period II were switched to usual care in the Extension Study.
Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the &quot;usual care&quot; treatment group in Period III.</description>
        </group>
        <group group_id="E3">
          <title>Montelukast</title>
          <description>Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.
Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at
their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CRISP dictionary</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="461"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Mydriasis (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="461"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Vomiting (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Abdominal (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Thirst (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Thirst (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Viral (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Appendicitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Gastroenteritis, Infectious (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Infection, Intra-Abdominal (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Meningitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory, Upper (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory, Upper (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pneumonia (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Pneumonia (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pneumonia, Bacterial (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pneumonia, Viral (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Infection, Eyelid (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug Overdose (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Drug Overdose (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Trauma (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Tachycardia (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Concussion (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase Increased (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hypokalemia (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Dehydration (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hyperkinesia (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hypersomnia (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Seizure Disorder (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Somnolence (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Somnolence (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Tremor (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar Disorder (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="461"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anomaly, Urogenital (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Asthma (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Asthma (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Bronchoconstriction (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hypoxemia (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Infiltrate, Pulmonary (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Sinusitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pallor (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CRISP dictionary</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="435" subjects_at_risk="461"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Otitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Otitis Media (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Otitis Media (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pain, Ear (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental Caries (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Diarrhea (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Diarrhea (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Gastroenteritis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Vomiting (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Vomiting (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Fever (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="164" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pain, Abdominal (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Pain, Abdominal (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Viral (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory, Upper (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory, Upper (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="192" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Influenza (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pneumonia (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Tonsillitis (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Tonsillitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Headache (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Asthma (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="217" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Bronchitis (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Bronchitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Congestion, Nasal (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Cough (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Cough (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Epistaxis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Laryngitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pharyngitis (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Pharyngitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="120" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Rhinitis (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Rhinitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Rhinitis, Allergic (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Rhinitis, Allergic (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Rhinorrhea (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Rhinorrhea (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Sinus Disorder (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Sinusitis (Period II)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="461"/>
              </event>
              <event>
                <sub_title>Sinusitis (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Urticaria (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Varicella (Period III)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

